# AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer

> **NCT00519233** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 13 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** AGS-1C4D4

## Key facts

- **NCT ID:** NCT00519233
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2014-05-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00519233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00519233, "AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00519233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*